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screening of TGFBR1, TGFBR2 and FLNA in familial mitral 
valve prolapse
Jan J.J. Aalberts






Maarten P. van den Berg




So far only mutations in the filamin A gene (FLNA) have been identified as causing familial mitral 
valve prolapse (MVP). Previous studies have linked dysregulation of the transforming growth factor 
beta (TGF-β) cytokine family to MVP. We investigated whether mutations in the TGF-β receptors 
genes type I (TGFBR1) and II (TGFBR2) underlie isolated familial MVP cases. Eight families with 
isolated familial MVP were evaluated clinically and genetically. Ventricular arrhythmias were present 
in five of the eight families and sudden cardiac death occurred in 6 patients. Tissue obtained during 
mitral valve surgery or autopsy was available for histologic examination in 6 cases; all demonstrated 
myxomatous degeneration. A previously described FLNA missense mutation (p.G288R) was 
identified in one large family, but no mutations were discovered in TGFBR1 or TGFBR2. Our results 
suggest that TGFBR1 and TGFBR2 mutations do not play a major role in isolated myxomatous 
valve dystrophy. Screening for FLNA mutations is recommended in familial myxomatous valvular 
dystrophy, particularly if X-linked inheritance is suspected.   
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introduCtion
Mitral valve prolapse (MVP) is a common cardiac abnormality with an estimated prevalence of 2-3%.1 
It is characterized by single or bileaflet systolic billowing of the mitral valve into the left atrium. 
There is often leaflet thickening and redundancy, histologically characterized by myxomatous 
degeneration (Barlow disease).2 The natural history of MVP varies from asymptomatic with normal 
life expectancy to serious complications such as significant mitral regurgitation (MR), bacterial 
endocarditis, thromboembolism and even sudden cardiac death.1,3,4 Although these complications 
are uncommon, MVP is the most frequent cause of isolated MR requiring mitral valve surgery.5,6 
MVP can be part of a generalized connective tissue disorder, especially Marfan syndrome 
(MFS) and sub-diagnostic variants, but usually occurs as an isolated anomaly.7  Isolated MVP cases 
are mostly sporadic but autosomal dominant or X-linked forms have been described. The gene 
encoding filamin A (FLNA) is located on the X-chromosome and was the first gene discovered to 
cause isolated myxomatous valvular dystrophy, of which MVP is the most common form (OMIM 
300017).8 Other studies have identified loci on chromosomes 11, 13, and 16 linked to familial MVP.9-
11 Connective tissue disorders, besides MFS, in which MVP can occur are, for example, Loeys-Dietz 
syndrome and Ehlers-Danlos syndrome.12,13 Dysregulation of the transforming growth factor beta 
(TGF-β) cytokine family is a key factor in the pathogenesis of these syndromes. In addition, Ng et 
al. found a relationship between dysregulation of TGF-β and the development of MVP in a murine 
model of MFS. In the prolapsing valves of the Marfan-mice there was increased activity and signaling 
of TGF-β.14 A recent study also found TGF-β upregulation in the mitral valves of patients with isolated 
myxomatous MVP.15 
We therefore investigated whether mutations in the genes encoding the TGF-β receptors type 
I (TGFBR1) and II (TGFBR2) underlie non-syndromal familial MVP. As FLNA mutations have been 
previously shown to cause myxomatous valvular dystrophy, we also screened our patients for 
mutations in this gene.
Methods
All families with isolated familial MVP known at our cardiogenetics outpatient clinics in two centers 
(University Medical Center Groningen and Antonius Hospital Sneek) were included in this study. 
Routine procedures at the cardiogenetics outpatient clinic include: complete evaluation of the 
index patient and constructing a pedigree. We provide letters for the index patients to give to family 
members at risk inviting them to our outpatient clinic for presymptomatic (“cascade”) screening.16 
The clinical and genetic data of the index patients and family members were retrieved from clinical 
records. MVP was defined as echocardiographic single or bileaflet prolapse of at least 2 mm beyond 
the long-axis annular plane. Prolapse with thickening of the valve leaflets greater than 5 mm was 
termed classic prolapse.17 Familial MVP was considered present if there were at least two first- or 
second-degree relatives with MVP. As part of routine procedures, written informed consent was 




Genomic DNA was isolated from peripheral blood samples according to standard protocols. 
Bidirectional direct sequencing of the coding regions and flanking intronic sequences of TGFBR1, 
TGFBR2 and FLNA was performed in all index patients, using the BigDye Terminator DNA sequencing 
kit (version 2.0). Results were analyzed by standard software packages. Conditions and primers are 
available upon request. 
resuLts
Clinical evaluation
Eight families with familial isolated MVP were evaluated; seven families from the University 
Medical Center Groningen (family A to G) and one family from the Antonius Hospital Sneek (family 
H). Characteristics of the patients are summarized in Table I and see Figure 1. for pedigrees of all 
families. None of the patients had other anomalies and MFS or other generalized connective tissue 
diseases were excluded in all patients. 
table i. Characteristics of the patients
Patient Age 
(years)
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E-1 29 F classic prolapse AML, 
mild MR







classic prolapse AML 
and PML, mild MR, mild 
annulus calcification, 
bicuspid aortic valve
classic prolapse AML 
and PML, bicuspid 
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H-1 26 M prosthetic valve, dilated 
left ventricle 














































AML: anterior mitral valve leaflet, AVR: aortic valve replacement, DDD-R, dual-dual-dual-rate, F: female, ICD: 
implantable cardioverter defibrillator, LV: left ventricular, M: male, MR: mitral regurgitation, MVR: mitral valve 
replacement, NA: not available, PML: posterior mitral leaflet, PVC: premature ventricular complex, SSS: sick 
sinus syndrome, VF: ventricular fibrillation, VT: ventricular tachycardia 
- not present
* sudden cardiac death
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Patient A-1 was a 39-year-old woman who was referred to our MFS outpatient clinic because 
of a long and slender body habitus and a mid-systolic click on auscultation of the heart. Aortic 
dimensions were normal on echocardiography but a prolapse of the anterior mitral valve leaflet 
(AML) and late systolic MR were discovered. No other signs of MFS were present. She had a 30-year-
old brother (patient A-2) with a prolapse of the AML accompanied by mild regurgitation. Aortic 
diameters were normal but he had a dilated left ventricle with a normal ejection fraction.
Patient B-1 was a 51-year-old woman who was also evaluated for a possible diagnosis of MFS. 
She had a classic prolapse of the AML and posterior mitral valve leaflet (PML) with moderate MR, 
aortic diameters were normal. Her brother (patient B-2) had died suddenly at the age of 34 years 
and autopsy had shown an abnormally formed mitral valve with myxomatous degeneration, 
aortic dimension were normal. Holter examination of patient B-1 showed frequent non-sustained 
ventricular tachycardias (VT). This, combined with her family history, was reason to implant a 
cardioverter defibrillator (ICD). Two months post implantation she experienced a sustained VT 
which was successfully terminated by the ICD. 
Patient C-1 was a 45-year-old woman who was evaluated because her brother (patient C-2) had 
died suddenly at the age of 36 years. Autopsy had documented a floppy mitral valve and a rupture of 
one of the chordae (Fig. 2). Aortic dimensions were normal. On microscopic examination there was 
extensive myxomatous degeneration of the mitral valve. Echocardiography of patient C-1 showed 
a prolapse of the AML and PML with mild late systolic MR. Her 17-year-old daughter (patient C-3) 
had a prolapse of the PML and late systolic MR. Patient C-1’s younger brother (patient C-4) was also 
figure 1. Pedigrees of all families. Filled symbols: individuals with a MVP. Filled symbols family H: individuals with 
a MVP and the FLNA missense mutation (p.G288.R). Patients H-5 and H-6 have the FLNA missense mutation but 
do not have a MVP. 
* denotes patients with (sustained) ventricular arrhythmias
49
Screening of TGFBR1, TGFBR2, and FLNA in familial MVP
4
evaluated. On echocardiography there was a prolapse of the AML and PML with mild late systolic 
MR. Aortic dimensions of patients C-1, C-3 and C-4 were normal.   
Patient D-1 was an 18-year-old woman who collapsed due to ventricular fibrillation while 
giving an oral presentation at high school. Cardiopulmonary resuscitation was unsuccessful. 
Autopsy demonstrated an enlarged and thickened mitral valve showing extensive myxomatous 
degeneration. Her uncle (patient D-2) had a prolapse of the AML with mild late systolic MR, but in 
contrast to his niece he had no thickening of the mitral valve. In both patients aortic dimensions 
were normal. Patient D-1’s father (patient D-3) had died aged 41 years of a non-cardiac cause when 
she was 17 years old, cardiac analysis was never performed. 
Patient E-1 was a 29-year-old woman who was evaluated because of familial occurrence 
of valvular heart disease. Echocardiography demonstrated a classic prolapse of the AML with 
moderate MR. Her brother (patient E-2) had a classic prolapse of the AML and PML with mild 
holosystolic MR. He had received a DDD-R pacemaker because of a “sick sinus syndrome” and a 
2nd degree atrioventricular block. They had a sister who had died neonatally of heart failure. The 
autopsy report mentioned a ‘glassy papillary thickening of all heart valves’. Their father (patient E-3) 
had a classic MVP, a tricuspid valve prolapse (TVP), and a bicuspid aortic valve. At the age of 44 years 
figure 2. Postmortem examination of the mitral valve of patient C-2, which, on measurement, revealed an 
expansion of the mitral valve area and dilatation of the mitral valve ring. The mitral valve leaflets were dome-




he was operated on because of severe aortic stenosis and severe MR, both valves being replaced by 
mechanical prostheses. Postoperatively a VVI pacemaker was implanted because of 3rd degree AV-
block. Four years later he died suddenly, but no autopsy was performed. All patients in this family 
had normal aortic diameters. 
Patient F-1 was a 54-year-old woman who was evaluated because her son (patient F-2) had died 
suddenly due to ventricular fibrillation (VF) at the age of 29 years. Autopsy had shown myxomatous 
degeneration of the mitral valve. Echocardiography of patient F-1 revealed a classic prolapse of 
the AML with mild MR. She received an ICD because of non-sustained VT-’s, unexplained syncope 
and her family history. Her daughter (patient F-3) was also screened and a prolapse of the AML was 
discovered. All patients in this family had normal aortic diameters. 
Patient G-1 was a 38-year-old woman who was evaluated because of palpitations. On 
echocardiography a classic prolapse of the AML was visible with moderate MR. Her sister (patient G-2) 
had a classic prolapse with late-systolic moderate MR. Both patients had normal aortic diameters. 
Patient H-1 was a 26-year-old man who was referred for evaluation of a possible genetic cause of 
his mitral valve pathology, aortic root dilatation (aortic root diameter: 39 mm; maximum predicted 
aortic root diameter: 36 mm) and dilated left ventricle.18 At the age of 3 years he had received a 
mechanical prosthetic valve (Björk-Shiley 23 mm) in the mitral valve position due to severe MR and 
figure 3. Microscopy (after hematoxylin and eosin staining) of the mitral valve leaflet of patient H-2  showing a 
superficial stromal nodule with surface fibrosis and extensive myxomatous change. Original magnification 200x.
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stenosis. He had a brother (patient H-2), who had died suddenly at the age of 19 years, who also 
had mitral valve pathology. Since his youth he had a classic prolapse of the AML and PML with 
myxomatous degeneration. In addition, the other valves (aortic, pulmonary and tricuspid) were also 
abnormal, being thickened and having abundant tissue. Furthermore, he had a muscular ventricular 
septal defect. At the age of 18 years he was operated on because of severe MR. Pathologic 
examination of the resected valve-tissue showed myxomatous degeneration (Fig. 3). One year later 
he died suddenly. Besides the known valve pathology, autopsy revealed no other anomalies. Their 
mother (H-3) and grandmother (H-4) were also evaluated and both had a prolapse of the AML. No 
anomalies were discovered on the echocardiogram of their aunt (H-5) and her daughter (H-6).
Genetic evaluation
TGFBR1, TGFBR2 and FLNA were analyzed by direct sequencing in all index-patients. This led to the 
identification of a previously described FLNA missense mutation (c.862G>A), leading to a change 
of amino acid glycine into arginine at position 288 (p.G288R) in family H.8 Family members were all 
shown to be carriers of the mutation. No mutations in TGFBR1 and TGFBR2 were identified and there 
were no FLNA mutations found in families A-G.
disCussion
Until now, only mutations in the FLNA gene have been demonstrated to cause isolated MVP. In 2007 
Kyndt et al. described 4 families having myxomatous valvular dystrophy, transmitted in an X-linked 
recessive pattern.8 They identified 4 different mutations in FLNA causing the valvular dystrophy; 3 
missense mutations and one 1944-bp genomic deletion of exons 16 to 19. 
FLNA is one of the 3 filamin genes expressed in humans and filamin A is a protein that crosslinks 
filamentous actin (an important component of the cytoskeleton) into orthogonal networks, 
contributing to both strength and flexibility of cells.19 The FLNA mutations lead to impaired binding 
abilities of filamin A which eventually influences the elastic properties of cells. As FLNA is located 
on the X-chromosome, women carrying FLNA mutations are usually unaffected or only mildly 
affected as they have another (normal) FLNA gene copy on their second X-chromosome. Besides a 
major component of the cytoskeleton, filamin A is also involved in the regulation of TGF-β signaling 
through interaction with SMADs (signal transducer- and transcriptional modulator-proteins).20 The 
TGF-β signaling pathway is one of the many regulatory pathways involved in controlling normal 
and abnormal cardiac valve development. Genetic deletion of SMAD6, which inhibits TGF-β 
signaling, causes atrioventricular canal and outflow tract valve primordial hyperplasia in mice.21 
TGF-β signaling plays a role in endocardial cushion formation and endothelial to mesenchymal 
transdifferentiation (EMT) of endocardial endothelial cells, a crucial step in the development of the 
mitral valve. In addition, when EMT is completed, TGF-β activity and other signaling mechanisms 
induce mesenchymal cell proliferation, another important process in the development of the mitral 
valve.22 Furthermore, TGF-β plays an important role in the pathogenesis of MFS and Loeys-Dietz 
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syndrome, in which MVP can be present. 
Based on the above premises, and a recent study demonstrating upregulation of TGF-β in the 
mitral valves of patients with isolated myxomatous MVP, we argued that isolated familial MVP might 
be caused by mutations in the TGF-β receptors I and II.15 However, we found no mutations in TGFBR1 
and TGFBR2 in our group of eight families, suggesting that mutations in these genes generally do 
not cause isolated familial MVP. This confirms earlier observations by Arrington et al. that TGFBR1 
and TGFBR2 mutations are absent in isolated valve pathology.23 Although our patient group was 
relatively small, it was well defined and important disease was clearly present; MVP affected all index 
patients, ventricular arrhythmias were present in at least 5 of the 8 families, and 6 family members 
had died suddenly. The high prevalence of ventricular arrhythmias and sudden cardiac death in our 
patient group is striking, although there might be a referral-bias to our tertiary center. Indeed the 
association between MVP and sudden cardiac death has been established, still the exact cause of 
the malignant ventricular arrhythmias remains obscure. In sudden death survivors with solely a MVP, 
a high background rate of complex ventricular ectopy (ventricular bigeminy and/or non-sustained 
VT) has been reported. This frequent ventricular ectopy might be caused by mechanical reasons 
from the MVP, but why they deteriorate in to even more malignant arrhythmias remains unknown.24
Although no mutations were identified in TGFBR1 and TGFBR2 in our patients, we did, however, 
identify a previously described p.G288R missense mutation in FLNA in family H. Phenotypic 
characteristics in this family varied from normal (patient H-5 and H-6) to asymptomatic, MVP (patient 
H-3 and H-4) in female carriers to early onset of polyvalvular pathology (patient H-2) and sudden 
death in affected males. Aortic root dilatation was also present in one of these patients (patient 
H-1). In the 4 families described by Kyndt et al., the cardiac phenotype was mainly characterized 
by dystrophy of the mitral and/or aortic valve.8 Involvement of the tricuspid and pulmonary valves 
occurred less frequently and aortic root dilatation was not reported.8 In Table II we summarize the 
clinical characteristics of all the patients having an p.G288R missense mutation in FLNA. Besides 
causing X-linked valvular dystrophy, FLNA mutations can also cause X-linked periventricular nodular 
heterotopia (OMIM 300017), X-linked chronic idiopathic intestinal pseudo-obstruction (OMIM 
300048), otopalatodigital syndrome types I and II (OMIM 311300), Melnick-Needles syndrome (OMIM 
309350), frontometaphyseal dysplasia (OMIM 305620) and FG syndrome-2 (OMIM 300321). Cardiac 
defects have been described in these diseases, for example aortic coarctation, aortic dilatation, 
aortic regurgitation, aortic stenosis, double outlet right ventricle, hypoplastic left ventricle, left 
ventricular noncompaction, mitral atresia, mitral valve prolapse, patent ductus arteriosus, and 
tricuspid valve prolapse.25-29 Although there are many (unknown) causes of these cardiac defects 
other than FLNA mutations, screening for FLNA mutations could be considered in unexplained 
cases, and in particular in the case of suspected X-linked inheritance.   
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ConCLusion
We screened 8 families with familial MVP for mutations in TGFBR1, TGFBR2 and FLNA. Importantly, 
malignant arrhythmias were present in at least five of them and sudden death occurred in six 
patients. In one family we discovered a previously described FLNA missense mutation but we 
found no TGFBR1 and TGFBR2 mutations, suggesting that such mutations do not play a major role 
in isolated myxomatous valvular dystrophy. These latter findings need to be confirmed in larger 
cohort studies. Screening for FLNA mutations is recommended in familial mitral valve dystrophy, 
particularly if X-linked inheritance is suspected. In other unexplained cardiac defects, screening 
for FLNA mutations could also be considered, again particularly if inheritance is suspected to be 
X-linked.
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table ii. overview of all patients so far described as having an p.G288r FLNA missense mutation
Patient Age at diagnosis sex Clinical characteristics 
H-III-5 26 years M Mitral valve pathology, dilated left ventricle and aortic root 
dilatation
H-III-6 19 years M Myxomatous degeneration mitral valve, thickened tricuspid, 
pulmonary and aortic valve, muscular VSD, sudden cardiac death
H-II-4 57 years F Normal 
H-II-5 50 years F Prolapse AML
H-I-2 86 years F Prolapse AML 
J-IV† 1 day M Dystrophy of all valves and an ASD, died of heart failure 24 hours 
after birth











Mitral and aortic valve disease (not further specified) 
Pan-valvular prolapse, bicuspid aortic valve, ASD
Pan-valvular prolapse, membranous VSD
 
† Described by Kindt et al.8  Due to the X-linked inheritance there must be two obligate female carriers in the 
family described by Kindt et al. However, they did not provide any clinical characteristics of these persons, so 
we have not added them to the table. 
‡ Described by Bernstein et al.30 They described an additional 2 female carriers but did not provide any clinical 
characteristics of these persons. So we have not added them to the table.  
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